CONTEXT: Acylated ghrelin is the putatively bioactive GH secretagogue. HYPOTHESIS: Estradiol (E2) stimulates the synthesis rather than inhibits the metabolic clearance of acylated ghrelin. SETTING: The study took place at an academic medical center. SUBJECTS:Healthy postmenopausal women participated. INTERVENTIONS: Interventions included prospectively randomized, double-blind separate-day iv infusions of saline or five graded doses of ghrelin in estrogen-deficient (n=12) and E2-supplemented (n=8) women. OUTCOMES: Metabolic clearance rate (MCR), volume of distribution, half-life, and secretion rate of acylated ghrelin were assessed. RESULTS: In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively. Transdermal E2 supplementation for 3 wk increased peak nighttime acylated ghrelin concentrations from 99+/-12 to 141+/-34 pg/ml (P=0.039). Exposure to E2 did not alter the linear relationships between 1) plasmaacylated ghrelin concentration and ghrelin infusion rate (638+/-12 slope units), 2) MCR of acylated ghrelin and ghrelin infusion rate (10+/-2.5 slope units), and 3) MCR and plasma concentration of acylated ghrelin (0.017+/-0.004 slope units). These data predict peak nighttime production rates of acylated ghrelin of 3.8+/-0.9 (E2) and 1.9+/-0.2 (no E2) ng/kg.min (P=0.039). CONCLUSION: Acylated ghrelin has a multifold larger distribution volume and MCR than total ghrelin. An estrogenic milieu augments synthesis and/or acylation of ghrelin peptide without altering its MCR.
RCT Entities:
CONTEXT: Acylated ghrelin is the putatively bioactive GH secretagogue. HYPOTHESIS: Estradiol (E2) stimulates the synthesis rather than inhibits the metabolic clearance of acylated ghrelin. SETTING: The study took place at an academic medical center. SUBJECTS: Healthy postmenopausal women participated. INTERVENTIONS: Interventions included prospectively randomized, double-blind separate-day iv infusions of saline or five graded doses of ghrelin in estrogen-deficient (n=12) and E2-supplemented (n=8) women. OUTCOMES: Metabolic clearance rate (MCR), volume of distribution, half-life, and secretion rate of acylated ghrelin were assessed. RESULTS: In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively. Transdermal E2 supplementation for 3 wk increased peak nighttime acylated ghrelin concentrations from 99+/-12 to 141+/-34 pg/ml (P=0.039). Exposure to E2 did not alter the linear relationships between 1) plasma acylated ghrelin concentration and ghrelin infusion rate (638+/-12 slope units), 2) MCR of acylated ghrelin and ghrelin infusion rate (10+/-2.5 slope units), and 3) MCR and plasma concentration of acylated ghrelin (0.017+/-0.004 slope units). These data predict peak nighttime production rates of acylated ghrelin of 3.8+/-0.9 (E2) and 1.9+/-0.2 (no E2) ng/kg.min (P=0.039). CONCLUSION: Acylated ghrelin has a multifold larger distribution volume and MCR than total ghrelin. An estrogenic milieu augments synthesis and/or acylation of ghrelin peptide without altering its MCR.
Authors: E Arvat; M Maccario; L Di Vito; F Broglio; A Benso; C Gottero; M Papotti; G Muccioli; C Dieguez; F F Casanueva; R Deghenghi; F Camanni; E Ghigo Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: N Nagaya; K Miyatake; M Uematsu; H Oya; W Shimizu; H Hosoda; M Kojima; N Nakanishi; H Mori; K Kangawa Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: O Gualillo; J E Caminos; M Kojima; K Kangawa; E Arvat; E Ghigo; F F Casanueva; C Diéguez Journal: Eur J Endocrinol Date: 2001-06 Impact factor: 6.664
Authors: N Nagaya; M Kojima; M Uematsu; M Yamagishi; H Hosoda; H Oya; Y Hayashi; K Kangawa Journal: Am J Physiol Regul Integr Comp Physiol Date: 2001-05 Impact factor: 3.619
Authors: K Takaya; H Ariyasu; N Kanamoto; H Iwakura; A Yoshimoto; M Harada; K Mori; Y Komatsu; T Usui; A Shimatsu; Y Ogawa; K Hosoda; T Akamizu; M Kojima; K Kangawa; K Nakao Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Catalina Norman; Nanette Rollene; Suanne M Weist; Jean R Wigham; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Johannes D Veldhuis; Dana Erickson; Jean Wigham; Sue Weist; John M Miles; Cyril Y Bowers Journal: J Clin Endocrinol Metab Date: 2011-05-25 Impact factor: 5.958
Authors: Lorenzo Leggio; William H Zywiak; Samuel R Fricchione; Steven M Edwards; Suzanne M de la Monte; Robert M Swift; George A Kenna Journal: Biol Psychiatry Date: 2014-03-25 Impact factor: 13.382
Authors: Jenny Tong; Nimita Dave; Ganesh M Mugundu; Harold W Davis; Bruce D Gaylinn; Michael O Thorner; Matthias H Tschöp; David D'Alessio; Pankaj B Desai Journal: Eur J Endocrinol Date: 2013-05-02 Impact factor: 6.664
Authors: Johannes D Veldhuis; Kristi L Mielke; Mihaela Cosma; Cacia Soares-Welch; Remberto Paulo; John M Miles; Cyril Y Bowers Journal: J Clin Endocrinol Metab Date: 2008-12-16 Impact factor: 5.958
Authors: Susan B Hudson; Darrell R Schroeder; Joy N Bailey; Kristi L Mielke; Dana Erickson; John M Miles; Cyril Y Bowers; Johannes D Veldhuis Journal: J Clin Endocrinol Metab Date: 2009-10-26 Impact factor: 5.958
Authors: Johannes D Veldhuis; Susan B Hudson; Dana Erickson; Joy N Bailey; George Ann Reynolds; Cyril Y Bowers Journal: Am J Physiol Endocrinol Metab Date: 2009-05-26 Impact factor: 4.310